Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
Posted on: Tuesday, 13 January 2009, 02:00 CST
UPPSALA,
(Logo: http://www.newscom.com/cgi-bin/prnh/20090113/333930 )
Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore(TM) surface plasmon resonance instruments and applications for fragment-based drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.
"We look forward to deepening our relationship with GE Healthcare and
About Beactica
Beactica AB is a specialist drug discovery company, utilising its
proprietary methodologies to evaluate the biophysical interaction of
molecules in order to generate novel therapeutics. The company was spun out
of
For further information, please contact Dr
SOURCE Beactica AB
Source: PR Newswire
Related Articles
- Members of Over 71 Million U.S. Households Ignored by Universal Healthcare
- Uppsala University and the Swedish Institute of Space Physics Collaborate with IBM In Large Scale Study of 'Space Weather'
- Beactica Announces Drug Discovery Agreement With Cubist Pharmaceuticals
- SURVEY: American Workers Want Universal Healthcare
- Study Polls Physician Views on Universal Healthcare
- Fortum and Uppsala University Sign Cooperation Agreement
- Standard Management/Universal Healthcare Company, LLC Announces Execution of Purchase Agreement To Acquire California Institutional Pharmacy
- Edwards Joins Cry for Universal Healthcare
- MedImmune and Infinity Pharmaceuticals Announce Cancer Drug Development and Worldwide Commercialization Agreement
 |
 |
User Comments (0)
RSS Feeds